Neurotensin: An endogenous antipsychotic? Commentary

Becky Kinkead, Charles Nemeroff

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Despite evidence from a variety of experimental approaches implicating the neuropeptide neurotensin in both the mechanism of action of antipsychotic drugs and the pathophysiology of schizophrenia, there has been some debate as to whether a peripherally administered neurotensin receptor agonist represents a sound strategy for the development of a novel class of antipsychotic drugs.

Original languageEnglish
Pages (from-to)99-103
Number of pages5
JournalCurrent Opinion in Pharmacology
Volume2
Issue number1
DOIs
StatePublished - Feb 1 2002
Externally publishedYes

Fingerprint

Neurotensin
Antipsychotic Agents
Neurotensin Receptors
Neuropeptides
Schizophrenia

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Neurotensin : An endogenous antipsychotic? Commentary. / Kinkead, Becky; Nemeroff, Charles.

In: Current Opinion in Pharmacology, Vol. 2, No. 1, 01.02.2002, p. 99-103.

Research output: Contribution to journalArticle

@article{41a85cd7288342bab01e97cb2101baab,
title = "Neurotensin: An endogenous antipsychotic? Commentary",
abstract = "Despite evidence from a variety of experimental approaches implicating the neuropeptide neurotensin in both the mechanism of action of antipsychotic drugs and the pathophysiology of schizophrenia, there has been some debate as to whether a peripherally administered neurotensin receptor agonist represents a sound strategy for the development of a novel class of antipsychotic drugs.",
author = "Becky Kinkead and Charles Nemeroff",
year = "2002",
month = "2",
day = "1",
doi = "10.1016/S1471-4892(01)00128-X",
language = "English",
volume = "2",
pages = "99--103",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Neurotensin

T2 - An endogenous antipsychotic? Commentary

AU - Kinkead, Becky

AU - Nemeroff, Charles

PY - 2002/2/1

Y1 - 2002/2/1

N2 - Despite evidence from a variety of experimental approaches implicating the neuropeptide neurotensin in both the mechanism of action of antipsychotic drugs and the pathophysiology of schizophrenia, there has been some debate as to whether a peripherally administered neurotensin receptor agonist represents a sound strategy for the development of a novel class of antipsychotic drugs.

AB - Despite evidence from a variety of experimental approaches implicating the neuropeptide neurotensin in both the mechanism of action of antipsychotic drugs and the pathophysiology of schizophrenia, there has been some debate as to whether a peripherally administered neurotensin receptor agonist represents a sound strategy for the development of a novel class of antipsychotic drugs.

UR - http://www.scopus.com/inward/record.url?scp=0036467316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036467316&partnerID=8YFLogxK

U2 - 10.1016/S1471-4892(01)00128-X

DO - 10.1016/S1471-4892(01)00128-X

M3 - Article

C2 - 11786316

AN - SCOPUS:0036467316

VL - 2

SP - 99

EP - 103

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

IS - 1

ER -